Fouzia Laghrissi-Thode
CIK 1642015 · View on SEC EDGAR ↗
Insider
First SEC filing: May 18, 2015 · Latest: June 5, 2026
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 11 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 3, 2026 | NERV | A | 50,000 | $4.68 | $234,000 | — | — | — | 6.0% (price as of 2026-08-21) |
| Dec. 5, 2024 | NERV | A | 12,500 | — | — | 12,500 Direct | — | Acquired | (price as of 2026-08-21) |
| Sept. 27, 2023 | NERV | A | 12,500 | — | — | 12,500 Direct | — | Acquired | (price as of 2026-08-21) |
| June 10, 2022 | NERV | A | 2,500 | — | — | 2,500 Direct | — | Acquired | (price as of 2026-08-21) |
| June 11, 2021 | NERV | A | 20,000 | — | — | 20,000 Direct | — | Acquired | (price as of 2026-08-21) |
| June 11, 2020 | NERV | A | 20,000 | — | — | 20,000 Direct | — | Acquired | (price as of 2026-08-21) |
| May 31, 2019 | NERV | A | 20,000 | — | — | 20,000 Direct | — | Acquired | (price as of 2026-08-21) |
| June 7, 2018 | NERV | A | 20,000 | — | — | 20,000 Direct | — | Acquired | (price as of 2026-08-21) |
| June 1, 2017 | NERV | A | 12,500 | — | — | 12,500 Direct | — | Acquired | (price as of 2026-08-21) |
| June 16, 2016 | NERV | A | 12,500 | — | — | 12,500 Direct | — | Acquired | (price as of 2026-08-21) |
| June 17, 2015 | NERV | A | 25,000 | — | — | 25,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Dec. 5, 2024 | NERV | Stock Option (right to buy) [F1] | Common Stock (12,500) | $2.12 | Dec. 4, 2034 | 12,500 | Acquired |
| Sept. 27, 2023 | NERV | Stock Option (right to buy) [F1] | Common Stock (12,500) | $7.30 | Sept. 26, 2033 | 12,500 | Acquired |
| June 10, 2022 | NERV | Stock Option (right to buy) [F1] | Common Stock | — | June 9, 2032 | 2,500 | Acquired |
| June 11, 2021 | NERV | Stock Option (right to buy) [F1] | Common Stock (20,000) | $2.90 | June 10, 2031 | 20,000 | Acquired |
| June 11, 2020 | NERV | Stock Option (right to buy) [F1] | Common Stock (20,000) | $3.40 | June 10, 2030 | 20,000 | Acquired |
| May 31, 2019 | NERV | Stock Option (right to buy) | Common Stock (20,000) | $5.21 | May 30, 2029 | 20,000 | Acquired |
| June 7, 2018 | NERV | Stock Option (Right to Buy) | Common Stock (20,000) | $8.25 | June 6, 2028 | 20,000 | Acquired |
| June 1, 2017 | NERV | Stock Option (Right to Buy) | Common Stock (12,500) | $10.00 | May 31, 2027 | 12,500 | Acquired |
| June 16, 2016 | NERV | Stock Option (right to buy) | Common Stock (12,500) | $10.20 | June 15, 2026 | 12,500 | Acquired |
| June 17, 2015 | NERV | Stock Option (right to buy) | Common Stock (25,000) | — | June 17, 2025 | 25,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| May 18, 2015 | NERV | Common Stock | 0 | Direct |